KingstronBio Successfully Completes First Implant of ProStyle M® Valve System in Major Clinical Study

A New Age in Cardiac Healthcare

On March 12, 2026, significant progress was made in cardiac healthcare when the first implantation of the ProStyle M® Transcatheter Mitral Valve System took place. This groundbreaking procedure was conducted by Professor Wang Chunsheng and Professor Wei Lai from the Department of Cardiac Surgery at Zhongshan Hospital, affiliated with Fudan University, and marks the beginning of a national multicenter confirmatory clinical study.

The ProStyle M®, developed by KingstronBio Technology (Changshu) Co., Ltd., represents a major advance in treating mitral regurgitation, a common heart valve condition, especially prevalent in China. This condition can lead to serious complications if left untreated. The introduction of this innovative transcatheter valve system is expected to offer patients safer and more effective treatment options.

Innovative Procedures with Advanced Technology
The ProStyle M® is designed using advanced techniques that minimize surgical challenges, such as left ventricular outflow tract obstruction and anchoring difficulties. The utilization of pure ultrasound guidance during implantation not only enhances precision but also emphasizes the system's design, aimed at easing surgical processes while ensuring outstanding hemodynamic performance.

Prior to this clinical study, the ProStyle M® underwent an exhaustive two-year First-in-Man (FIM) study involving a cohort of 10 individuals, all over the age of 71. The results were promising; all patients experienced excellent anchoring performance, with no incidences of valve regurgitation observed. As the multicenter study progresses, KingstronBio aims to provide further evidence to ensure the product’s safety and efficacy in broader patient populations.

KingstronBio's Commitment to Innovation
At the heart of KingstronBio’s operations is a commitment to innovation within the structural heart disease sector. With a portfolio that spans artificial bioprosthetic heart valves, valve annuloplasty rings, and cardiac surgical biopatches, the company leverages patented technologies such as Micro-Ex™ and AirBo™. These technologies aim to enhance the durability and performance of heart valves, setting KingstronBio apart in the competitive landscape of medical device development.

Micro-Ex™ is a cutting-edge anti-calcification treatment process that removes unwanted phospholipids and cell debris, which can lead to deterioration of valve function over time. AirBo™ technology further aids in maintaining the valvular integrity by ensuring proper dry storage of the valve, thereby enhancing its longevity and compatibility with human tissue.

The Future of Transcatheter Mitral Valve Replacement
Mitral regurgitation (MR) has remained a complex challenge in cardiac intervention due to the unique anatomical issues presented by each patient. Transcatheter Mitral Valve Replacement (TMVR) has revolutionized approaches to treatment in this field, yet it has historically been susceptible to various technical challenges. KingstronBio’s ProStyle M® aims to address these concerns through its innovative design and technology.

As clinical studies proceed, the potential for ProStyle M® to transform cardiac care is immense. The advantages of non-invasive procedures provided by transcatheter technology align with the needs of many patients who suffer from MR, looking for less invasive treatment alternatives.

Conclusion
In summary, the first successful implantation of the ProStyle M® Transcatheter Mitral Valve System is not just a milestone for KingstronBio; it is a beacon of hope for patients worldwide dealing with structural heart diseases. With a firm focus on research, development, and innovation, KingstronBio is set to redefine the landscape of cardiac healthcare, paving the way for a healthier future.